We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Talzenna

News List

Pfizer secures EC approval for oral PARP inhibitor Talzenna pharmaceutical-technology
June 26, 2019
Pfizer has secured approval from the EC for Talzenna (talazoparib) as a monotherapy to treat adult patients with germline breast cancer with gBRCA gene mutations.
Pfizer’ Talzenna leads latest CHMP highlights pharmatimes
April 29, 2019
Thirteen medicines were recommended for approval at the Committee’s April 2019 meeting, including two orphan medicines……
Pfizer’s Talzenna cleared for breast cancer pharmatimes
October 19, 2018
US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.